
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc is experiencing a positive outlook driven by increased revenue estimates for its products, particularly the Brinsupri NCFB, which has seen its peak sales estimate rise to approximately $8.5 billion, reflecting enhanced market confidence. The company is also adjusting revenue projections for its emerging therapies, including Treprostinil Palmitil Inhalation Powder for idiopathic pulmonary fibrosis (IPF), suggesting a diversified and strengthening pipeline. Additionally, a reduced terminal decline rate in the discounted cash flow (DCF) analysis indicates heightened confidence in the longevity and sustainability of Insmed's revenue generation potential.
Bears say
Insmed Inc faces significant risks related to potential delays in clinical trials and regulatory approvals for its key products, which could adversely impact the company's overall valuation. Specifically, both Brensocatib and Treprostinil Palmitil Inhalation Powder are likely to encounter extensive timelines, with estimates suggesting TPIP may not penetrate the idiopathic pulmonary fibrosis (IPF) market until 2034, contingent on other drug approvals. Such delays in product development and market entry could significantly diminish the probability of success for Insmed, leading to a negative financial outlook.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares